What question did this study set out to answer?

This research aims to evaluate the short-term response and safety of protease inhibitor therapy in HIV-infected children.

Protease Inhibitor Therapy in HIV-Infected Children

View Full Paper

Ask AI

Bookmark

Authors

Retrospective review shows PI therapy improves immune response in HIV-positive children, highlighting safety and compliance issues.

This research aims to evaluate the short-term response and safety of protease inhibitor therapy in HIV-infected children.
Retrospective chart review at two urban pediatric HIV centers
Included 70 HIV-infected children receiving 101 PI containing antiretroviral therapy combinations
Main outcome measures were follow-up CD4 counts, viral loads, and compliance reports from patients or caregivers.
Mean increase in CD4+ lymphocyte count was 454 x 10(6)/L
Of 32 patients achieving undetectable viral loads, 28 (87.5%) maintained undetectability after an average of 8.9 months
19 of 101 therapy courses had significant side effects, including renal complications in 8 of 21 patients treated with indinavir.

Feingold et al. (2000) studied this question.

View Full Paper

Ask AI

Bookmark